2/25
11:03 am
oric
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]
Low
Report
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]
2/24
10:58 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at HC Wainwright from $23.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at HC Wainwright from $23.00 to $25.00. They now have a "buy" rating on the stock.
2/24
08:54 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
2/24
07:01 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/24
03:01 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
2/23
04:05 pm
oric
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
High
Report
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
2/6
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/5
04:01 pm
oric
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
1/13
08:42 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
1/12
08:30 am
oric
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Low
Report
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
1/9
06:10 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
1/7
06:05 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/6
04:05 pm
oric
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/8
09:27 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
12/8
07:22 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/5
08:00 pm
oric
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
12/5
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/5
01:00 am
oric
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
12/4
09:45 pm
oric
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025